PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

atropine Side Effects

The reactions most often reported to the FDA for atropine (also sold as AtroPen), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

7,881
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2000 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of atropine come from 7,881 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 7,881 reports to the FDA Adverse Event Reporting System (FAERS) for atropine (AtroPen): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

7,881

Reports Mentioning Death

1,594

20.2% of reports — not proof the medicine caused the death

Hospitalizations

3,432

43.5% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DIARRHOEA
535
HYPOTENSION
485
NAUSEA
458
DEATH
445
DYSPNOEA
394
FATIGUE
383
BRADYCARDIA
381
VOMITING
363
PAIN
341
CARDIAC ARREST
308
TOXICITY TO VARIOUS AGENTS
289
PYREXIA
287
HYPERTENSION
251
DRUG INTERACTION
246
FALL
239
HEADACHE
236
TACHYCARDIA
231
CONSTIPATION
228

Who Reports Side Effects

Gender Distribution

Female 3,418 (49%)
Male 3,486 (50%)
Unknown 58

Age Distribution

0-17 626 (11%)
18-44 1,158 (20%)
45-64 1,884 (33%)
65-74 1,200 (21%)
75+ 872 (15%)

Reporting Trend by Year

2000 2025

Reactions in Death Reports

Top reactions reported in 1,594 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 443
CARDIAC ARREST 137
DIARRHOEA 128
FATIGUE 111
NAUSEA 106
HYPOTENSION 104
VOMITING 100
PNEUMONIA 96
DYSPNOEA 91
RESPIRATORY FAILURE 91
ASTHENIA 87
DISEASE PROGRESSION 85
PAIN 85
RENAL FAILURE 82
TOXICITY TO VARIOUS AGENTS 76
BRADYCARDIA 73
CARDIO-RESPIRATORY ARREST 73
ANAEMIA 62

Reactions in Hospitalization Reports

Top reactions in 3,432 reports where hospitalization was an outcome.

Reaction Reports
HYPOTENSION 348
DIARRHOEA 282
DYSPNOEA 251
PAIN 240
BRADYCARDIA 232
TOXICITY TO VARIOUS AGENTS 212
PYREXIA 206
VOMITING 196
NAUSEA 191
FALL 186
CARDIAC ARREST 162
DRUG INTERACTION 161
PNEUMONIA 154
FEBRILE NEUTROPENIA 148
CONSTIPATION 145
FATIGUE 143
HYPERTENSION 138
TACHYCARDIA 130

Compare atropine vs adenosine →

What the FAERS Data Reveals About atropine Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 7,881 voluntary reports linked to atropine and its brand equivalents (AtroPen), spanning 2000 through 2025. Of those, 1,594 (20.2%) listed death as an outcome and 3,432 (43.5%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 49% were female and 50% male; age distribution skews toward 45-64, with 1,884 reports in that bracket. The single most reported reaction is diarrhoea with 535 submissions, followed by hypotension and nausea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.